Why Two Heart Drug Trials Failed: Novo Nordisk, Novartis — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Readout LOUD podcast examined why two large clinical trials for heart drugs — developed by Novo Nordisk and Novartis respectively — failed despite billions in dollars of pharma industry investment.
- Ethan Weiss, cardiologist and biotech entrepreneur, joined as guest to discuss the surprising trial failures and their long-term implications for the development of new heart medicines.
- The episode also recapped a spurt of FDA drug approvals that occurred while the show was on hiatus.
- Merck and Moderna's upcoming cancer treatment was highlighted in the recap as the next big development in oncology.
Why it matters: Two heart drug trials backed by billions in pharma investment from Novo Nordisk and Novartis failed despite being heralded as the next era in heart disease treatment, representing a significant setback for the cardiovascular drug pipeline. The episode's discussion with cardiologist Ethan Weiss directly addresses what went wrong and what companies should pursue instead.
Ask SkimNews
